Nicholas Boston
@Highvista Strategies Llc
Latest period2024 - Q3ReportedManaged Assets$289.961MTotal holdings142
Assets growth rate5.92%Assets growth rate (2-Q avg)1.78%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Highvista Strategies Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 142 positions.
Assets under management
The assets under management (AUM) of Highvista Strategies Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 289.961M in assets, with a quarterly growth rate of 5.92% and a 2-quarter average growth rate of 1.78%. The portfolio is managed by Nicholas Boston, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
AMZNAmazon Com Inc
| 2.07% | $5.999M 32,193 shares@ $186.34 avg price | Increased 78.92% |
PCVXVaxcyte Inc
| 1.77% | $5.103M 44,661 shares@ $114.27 avg price | Increased 38.22% |
ACLXArcellx Inc
| 1.59% | $4.605M 55,139 shares@ $83.52 avg price | Increased 8.04% |
XPOXpo Inc
| 1.4% | $4.051M 37,680 shares@ $107.52 avg price | Increased 47.89% |
PTGXProtagonist Therapeutics Inc
| 1.39% | $4.028M 89,508 shares@ $45.0 avg price | Increased 321.64% |
ARGXArgenx Se
| 1.34% | $3.878M 7,154 shares@ $542.08 avg price | Increased 8.33% |
BCYCBicycle Therapeutics Plc
| 1.09% | $3.158M 139,544 shares@ $22.64 avg price | Increased 9.66% |
KROSKeros Therapeutics Inc
| 1.05% | $3.026M 52,107 shares@ $58.07 avg price | Increased 32.9% |
NUVLNuvalent Inc
| 1.03% | $2.969M 29,018 shares@ $102.3 avg price | Increased 1.12% |
XENEXenon Pharmaceuticals Inc
| 1.01% | $2.904M 73,762 shares@ $39.38 avg price | Increased 1.44% |